Protein Intake and Exercise-induced Muscle Damage
Launched by RADBOUD UNIVERSITY MEDICAL CENTER · Jan 29, 2024
Trial Information
Current as of July 05, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how different protein strategies can help reduce muscle damage after exercise in older adults who are physically active. Specifically, the researchers want to see if using whey protein, mixed plant-based protein, or protein-rich food products can be more effective than eating carbohydrates alone. The trial involves participants who are 60 years or older, can walk long distances (30-50 km per day), and usually consume less protein than recommended.
Participants will follow one of the protein strategies or the carbohydrate control for five weeks. They will be asked to complete a long walking event during the study and will answer questionnaires and provide blood samples to measure muscle damage. It's important to note that individuals with milk allergies, diabetes, certain intestinal diseases, or those using other protein supplements will not be eligible to participate. This study aims to provide valuable insights into how older adults can better manage muscle health through diet and exercise.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 60 years or older
- • Registered for the Nijmegen Four Days Marches (i.e., able to walk 30-50 km/day)
- • A habitual protein intake \<1.0 g/kg/d based on the protein 55+ (PRO55+) screening tool
- • Able to understand and perform the study procedures
- • Able to use a mobile device
- Exclusion Criteria:
- • Allergic or sensitive for milk proteins, or lactose intolerant
- • Diagnosed type I or type II diabetes mellitus
- • Diagnosed intestinal diseases influencing the uptake of protein (i.e., active inflammatory bowel disease, Crohn's disease)
- • Consumption of other freely available protein supplements during the study period.
- • If the subject intends to perform additional exercise bouts that cause muscle damage in the 4 days before the single- and multiple exercise bouts.
About Radboud University Medical Center
Radboud University Medical Center is a leading academic medical institution located in Nijmegen, the Netherlands, dedicated to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, Radboud UMC leverages its multidisciplinary expertise to conduct high-quality research that aims to improve patient outcomes and enhance medical knowledge. The center is committed to ethical standards and regulatory compliance, fostering collaboration among researchers, healthcare professionals, and patients to translate scientific discoveries into effective clinical applications. With a focus on personalized medicine and cutting-edge technologies, Radboud University Medical Center plays a pivotal role in shaping the future of healthcare through its rigorous clinical trial initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nijmegen, Gelderland, Netherlands
Patients applied
Trial Officials
Maria Hopman, prof. dr.
Principal Investigator
Radboud University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported